Clinico-pathological features of MET exon 14 mutation positive NSCLC in the UK
Benafif, S. Greystoke, A. Carter, Mathew Bulusu, R. Baijal, S. Conibear, J. Nintos, G. Papadatos-Pastos, D. Ahmad, T. Lee, S. M
Benafif, S.
Greystoke, A.
Carter, Mathew
Bulusu, R.
Baijal, S.
Conibear, J.
Nintos, G.
Papadatos-Pastos, D.
Ahmad, T.
Lee, S. M
Citations
Altmetric:
Abstract
Introduction: MET exon 14 skip mutation-driven lung cancer
makes up 3-4% of non-small cell lung cancer (NSCLC). Unlike EGFR
associated NSCLC, an association with a smoking history and older
age has been described in this subset of NSCLC. Here, we describe a
UK cohort of MET mutation positive NSCLC patients.
Methods: A retrospective review of MET mutation positive NSCLC
cases treated at 7 UK centres was carried out. Information collected
included baseline characteristics, response to treatment and
outcomes.
Results: 30 patients were diagnosed with MET mutation positive
NSCLC between 2013 and December 2020. Median follow-up
duration from NSCLC diagnosis was 17.5 months. Median age was
76 years (42-86); male to female ratio was 1:1. 67% were current
or ex-smokers. MET exon 14 skip mutation was present in 30 cases,
1 of which also carried MET amplification. The most common comutations
were observed in TP53 (9/30). PDL1 IHC for 18 patients
showed 61% had a score of ≥50%, 22% had a score of 1-49% and 17%
were negative. Baseline staging was reported as M0 in 43% (13/30),
M1a in 13% (4/30) and M1b/c in 43% (13/30). Brain metastases
were diagnosed in 6/30 (20%), 2 of which were at baseline. Radical
treatment was performed in 9 (30%) cases with either surgery
or chemoradiation. 26 patients received systemic treatment for
advanced NSCLC. The commonest first-line systemic treatment was
immunotherapy in 35% (9/26), followed by chemotherapy in 27%
(7/26). Table 1 summarises outcomes of patients treated with a MET
inhibitor (METi).
Conclusions: NSCLC characteristics in this UK cohort are similar to
those described elsewhere. Of those patients who received a METi,
most achieved PR. UK approval of METi agents is awaited, but with
increasing access to extended molecular profiling for NSCLC, more
patients that may benefit from these agents will continue to be
identified.
Description
Date
2021
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Benafif S, Greystoke A, Carter M, Bulusu R, Baijal S, Conibear J, et al. Clinico-pathological features of MET exon 14 mutation positive NSCLC in the UK. Lung Cancer . 2021 Jun;156:S46.